Regorafenib Phase I Study in Mainland Chinese Patients
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to define the pharmacokinetic of Regorafenib
administered orally as a single agent in Chinese patients with advance solid tumors.
The second objective include the evaluation of safety, tolerability, and efficacy of Chinese
patents treated with Regorafenib